Ofatumumab treatment in lupus nephritis patients

Rituximab is frequently used in systemic lupus erythematosus; however, side effects such as infusion-related reactions limit its use. In this case report, we describe, for the first time, treatment with ofatumumab in four patients with lupus nephritis. The treatment was well tolerated in three of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Haarhaus, Malena Loberg, Svenungsson, Elisabet, Gunnarsson, Iva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Kidney in Systemic Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957712/
https://www.ncbi.nlm.nih.gov/pubmed/27478595
http://dx.doi.org/10.1093/ckj/sfw022
_version_ 1782444208917839872
author Haarhaus, Malena Loberg
Svenungsson, Elisabet
Gunnarsson, Iva
author_facet Haarhaus, Malena Loberg
Svenungsson, Elisabet
Gunnarsson, Iva
author_sort Haarhaus, Malena Loberg
collection PubMed
description Rituximab is frequently used in systemic lupus erythematosus; however, side effects such as infusion-related reactions limit its use. In this case report, we describe, for the first time, treatment with ofatumumab in four patients with lupus nephritis. The treatment was well tolerated in three of the patients, and a reduction of proteinuria was seen in all cases. This emphasizes the importance of alternative B-cell-depleting therapies in patients with an initial good response to rituximab, but who develop side effects.
format Online
Article
Text
id pubmed-4957712
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-49577122016-07-29 Ofatumumab treatment in lupus nephritis patients Haarhaus, Malena Loberg Svenungsson, Elisabet Gunnarsson, Iva Clin Kidney J Kidney in Systemic Disease Rituximab is frequently used in systemic lupus erythematosus; however, side effects such as infusion-related reactions limit its use. In this case report, we describe, for the first time, treatment with ofatumumab in four patients with lupus nephritis. The treatment was well tolerated in three of the patients, and a reduction of proteinuria was seen in all cases. This emphasizes the importance of alternative B-cell-depleting therapies in patients with an initial good response to rituximab, but who develop side effects. Oxford University Press 2016-08 2016-06-05 /pmc/articles/PMC4957712/ /pubmed/27478595 http://dx.doi.org/10.1093/ckj/sfw022 Text en © The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Kidney in Systemic Disease
Haarhaus, Malena Loberg
Svenungsson, Elisabet
Gunnarsson, Iva
Ofatumumab treatment in lupus nephritis patients
title Ofatumumab treatment in lupus nephritis patients
title_full Ofatumumab treatment in lupus nephritis patients
title_fullStr Ofatumumab treatment in lupus nephritis patients
title_full_unstemmed Ofatumumab treatment in lupus nephritis patients
title_short Ofatumumab treatment in lupus nephritis patients
title_sort ofatumumab treatment in lupus nephritis patients
topic Kidney in Systemic Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957712/
https://www.ncbi.nlm.nih.gov/pubmed/27478595
http://dx.doi.org/10.1093/ckj/sfw022
work_keys_str_mv AT haarhausmalenaloberg ofatumumabtreatmentinlupusnephritispatients
AT svenungssonelisabet ofatumumabtreatmentinlupusnephritispatients
AT gunnarssoniva ofatumumabtreatmentinlupusnephritispatients

Ejemplares similares